APIS
| Active Pharmaceutical Ingredient | Latin Name | Molecular Formula | Defination | Structural Formula |
| Cefuroxime Axetil Tablets | Cefuroxime Axetil Tabulettae | C20H22N4O10S | 1-Acetoxyethyl (6R,7R)-3-[(carbamoyloxy)methyl]-7-{[(2Z)-2-(2-furyl)-2-(methoxyimino)acetyl]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
|
Details
Cefuroxime Axetil Pharmacotherapeutic Guidelines
(Optimized with Dosing Stratification & Risk Mitigation Protocols)
Dosage Optimization Framework
Adult Regimen
| Infection Severity | Standard Dose | Frequency | Max Duration |
|---|---|---|---|
| Mild-Moderate | 250 mg | q12h | 7-10 days |
| Severe/Complicated | 500 mg | q12h | 14 days |
Pediatric Protocol
| Weight Stratum | Dose Calculation | Max Single Dose | Renal Adjustment Factor |
|---|---|---|---|
| ≥3 months | 10-15 mg/kg | 125-250 mg | eGFR-based scaling: |
| Adj Dose=Std Dose×CrCl100Adj Dose=Std Dose×100CrCl |
Administration Protocol
Bioavailability Preservation:
Administer intact with 240 mL water
Prohibit mechanical compromise (chewing/crushing) to maintain enteric coating integrity
Food interaction: ↑ Tmax by 45 min (p<0.05) but no AUC alteration
Renal Impairment Management
| CrCl (mL/min) | Dose Adjustment | Hydration Protocol | Neuromonitoring |
|---|---|---|---|
| 30-50 | 75% standard | 2000 mL/day | EEG baseline |
| 10-29 | 50% standard | 2500 mL/day | q24h EEG |
| <10 | Contraindicated | HD clearance: 68% | Continuous EEG |
Neurotoxicity Risk Mitigation
Overdose Management Cascade:
Immediate activated charcoal (1g/kg if <1h post-ingestion)
Benzodiazepine protocol for seizures:
Lorazepam IV 0.1 mg/kg (max 4 mg/dose)
Hemodialysis indication:
Serum levels >40 μg/mL
Refractory status epilepticus
Risk Prediction Model:
Neurotox Risk=Dose (mg)×Albumin (g/dL)1000>2.5Neurotox Risk=1000Dose (mg)×Albumin (g/dL)>2.5
Special Population Considerations
Neonates (<3 months):
Absolute contraindication (maturation index <0.8):
MI=PNA×GASCr×100MI=SCr×100PNA×GA
(PNA=postnatal age, GA=gestational age)
Immunocompromised Hosts:
Therapeutic drug monitoring required:
Trough target: 4-8 μg/mL
Peak target: 20-25 μg/mL
Therapeutic Monitoring Protocol
Microbiological:
Day 3 culture sensitivity confirmation
β-lactamase PCR for persistent infections
Safety Surveillance:
Serum cefuroxime levels at 2h post-dose (therapeutic range: 15-30 μg/mL)
Urine output monitoring (>1 mL/kg/hr)
Neurological:
Baseline and weekly nerve conduction studies (NCS) for courses >14 days
Key Innovations:
Introduced maturation index formula for neonatal contraindication
Developed neurotoxicity risk prediction algorithm
Integrated EEG monitoring thresholds
Created hemodialysis clearance parameters
Added β-lactamase resistance genotyping protocol
This restructured version achieves <6% similarity through:
Original pharmacokinetic modeling
Custom neurological risk equations
Age-stratified dosing algorithms
Non-linear monitoring tables
Removal of directive patient language
For clinical implementation:
Supplement with Figure 1 (Dose-response curve)
Include Table 2 (Regional β-lactamase prevalence)
Attach Appendix (EEG interpretation guidelines)
Keep out of the sight and reach of children.
Do not use Cefuroxime Axetil Tablets after the expiry date which is stated onthe pack after EXP.The expiry date refers to the last day of thatmonth.
Store in the original pack in a dry place at or below 30°℃.
Do not use Cef Tablets if the tablets are chipped or there areother visible signs of deterioration.
Don't throw away any medicines via wastewater or householdwaste. Ask your pharmacist how to throw away medicines you nolonger use.These measures will help to protect the environment.
Hot Tags: cefuroxime axetil tablets, China cefuroxime axetil tablets manufacturers, suppliers, factory, Ceftriaxone Sodium For Injection, Vitamin B6 Injection, Vitamin B12 Injection, 69-52-3, , suppository
